Abstract P1-18-05: Subcutaneous trastuzumab and hyaluronidase-oysk with intravenous pertuzumab and docetaxel in HER2-positive advanced breast cancer: Final analysis of the phase IIIb, multicenter, open-label, single-arm MetaPHER study
Sherko Kümmel(Kliniken Essen-Mitte), Miguel Martín(Hospital General Universitario Gregorio Marañón), Carlo Tondini(Ospedale Papa Giovanni XXIII), Servando Cardona‐Huerta(Tecnológico de Monterrey), Zbigniew Nowecki(The Maria Sklodowska-Curie National Research Institute of Oncology), Marco Sequi(Roche (Switzerland)), Eleonora Restuccia(Roche (Switzerland)), Alejandro Juarez, Erika Hitre(National Institute of Oncology), Bogusława Karaszewska(State University of Applied Sciences in Konin), Flavia Morales-Vásquez(Secretaria de Salud), Adam Knott(Roche (United Kingdom)), José Manuel Pérez García(Vall d'Hebron Institute of Oncology), Jacinta Abraham(Velindre NHS Trust), Estefanía Monturus(Roche (Switzerland)), Mark Benyunes(Roche (Switzerland)), Bartosz Itrych(Centralny Szpital Kliniczny)
Cited by 0
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k